Cancer immunoediting from immune surveillance to immune escape

被引:787
作者
Kim, Ryungsa [1 ]
Emi, Manabu
Tanabe, Kazuaki
机构
[1] Hiroshima Univ, Int Radiat Informat Ctr, Res Inst Radiat Biol & Med, Hiroshima 724, Japan
[2] Hiroshima Univ, Dept Surg Oncol, Res Inst Radiat Biol & Med, Hiroshima 724, Japan
关键词
cancer; immune escape; immune surveillance; immunoediting;
D O I
10.1111/j.1365-2567.2007.02587.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cancer immune surveillance is considered to be an important host protection process to inhibit carcinogenesis and to maintain cellular homeostasis. In the interaction of host and tumour cells, three essential phases have been proposed: elimination, equilibrium and escape, which are designated the 'three E's'. Several immune effector cells and secreted cytokines play a critical role in pursuing each process. Nascent transformed cells can initially be eliminated by an innate immune response such as by natural killer cells. During tumour progression, even though an adaptive immune response can be provoked by antigen-specific T cells, immune selection produces tumour cell variants that lose major histocompatibility complex class I and II antigens and decreases amounts of tumour antigens in the equilibrium phase. Furthermore, tumour-derived soluble factors facilitate the escape from immune attack, allowing progression and metastasis. In this review, the central roles of effector cells and cytokines in tumour immunity, and the escape mechanisms of tumour cells during tumour progression are discussed.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 130 条
[1]  
AFFABRIS E, 1987, HAEMATOLOGICA, V72, P76
[2]   CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs [J].
Agrawal, S ;
Marquet, J ;
Delfau-Larue, MH ;
Copie-Bergman, C ;
Jouault, H ;
Reyes, F ;
Bensussan, A ;
Farcet, JP .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (09) :1715-1723
[3]   HUMAN INTERFERON-INDUCIBLE PROTEIN-10 IS A POTENT INHIBITOR OF ANGIOGENESIS IN-VIVO [J].
ANGIOLILLO, AL ;
SGADARI, C ;
TAUB, DD ;
LIAO, F ;
FARBER, JM ;
MAHESHWARI, S ;
KLEINMAN, HK ;
REAMAN, GH ;
TOSATO, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :155-162
[4]  
[Anonymous], 1999, J IMMUNOL
[5]   Production of type I interferons: plasmacytoid dendritic cells and beyond [J].
Asselin-Paturel, C ;
Trinchieri, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (04) :461-465
[6]   Hsp90 binds CpG oligonucleotides directly:: implications for Hsp90 as a missing link in CpG signaling and recognition [J].
Bandholtz, L ;
Guo, Y ;
Palmberg, C ;
Mattsson, K ;
Ohlsson, B ;
High, A ;
Shabanowitz, J ;
Hunt, DF ;
Jörnvall, H ;
Wigzell, H ;
Agerberth, B ;
Gudmundsson, GH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2003, 60 (02) :422-429
[7]  
Beck C, 2001, MICROSC RES TECHNIQ, V52, P387, DOI 10.1002/1097-0029(20010215)52:4<387::AID-JEMT1023>3.0.CO
[8]  
2-W
[9]   Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes [J].
Bellamy, WT ;
Richter, L ;
Sirjani, D ;
Roxas, C ;
Glinsmann-Gibson, B ;
Frutiger, Y ;
Grogan, TM ;
List, AF .
BLOOD, 2001, 97 (05) :1427-1434
[10]   CANCER RISK AFTER RENAL-TRANSPLANTATION IN THE NORDIC COUNTRIES, 1964-1986 [J].
BIRKELAND, SA ;
STORM, HH ;
LAMM, LU ;
BARLOW, L ;
BLOHME, I ;
FORSBERG, B ;
EKLUND, B ;
FJELDBORG, O ;
FRIEDBERG, M ;
FRODIN, L ;
GLATTRE, E ;
HALVORSEN, S ;
HOLM, NV ;
JAKOBSEN, A ;
JORGENSEN, HE ;
LADEFOGED, J ;
LINDHOLM, T ;
LUNDGREN, G ;
PUKKALA, E .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (02) :183-189